If you have been reading about lyophilized powder and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-09-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
The mod received positive reviews from PC Games and PC Action. Planet Half-Life called it "A true masterpiece". Wanted! – A Wild West-style mod which follows a town Sheriff and his hunt for a bandit. Enemies include rattlesnakes, Native Americans and other outlaws. It contains original voice acting and era-specific weapons, and was created by Maverick Developments and released as a free mod. For some time it was bundled with the retail version of Counter-Strike, along with another mod by Maverick Developments, Absolute Redemption which was a chapter set between Half-Life and Half-Life 2.
=== Microdase === Microdase is a modified oxidase test used to differentiate Micrococcus from Staphylococcus by testing for the presence of cytochrome c. A positive result produces a dark color around the inoculant while negative result produces no color change.
== External links == CD98+Antigens at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Large+Neutral+Amino+Acid-Transporter+1 at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Amino+Acid+Transport+System+L at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
== Patents == "Coaxial Flow Post Capillary Mixing", J.W. Jorgenson and D.J. Rose, U.S. Patent No. 4,936,974. "Microelectrospray Method and Apparatus", J.W. Jorgenson and D.M. Dohmeier, U.S. Patent No. 5,115,131. "Two-Dimensional High-Performance Liquid Chromatography/Capillary Electrophoresis", J.W. Jorgenson and M.M. Bushey, U.S. Patent No. 5,131,998. "Two-Dimensional High-Performance Liquid Chromatography/Capillary Electrophoresis", J.W. Jorgenson and M.M. Bushey, U.S. Patent No. 5,240,577. "Method and Device for High Speed Separation of Complex Molecules", J.W. Jorgenson and C.A. Monnig, U.S. Patent No. 5,269,900. "Two-Dimensional Separation System", J.W. Jorgenson and A.V. Lemmo, U.S. Patent No. 5,389,221. "Two-Dimensional Separation System", J.W. Jorgenson and A.V. Lemmo, U.S. Patent No. 5,496,460. “Sample injector system for liquid chromatography”, Gerhardt; Geoff C., Jorgenson; James W., Fadgen; Keith, U.S. Patent No. 8,173,070
=== Carcinogenesis === There is a significant body of published literature suggesting a strong mechanistic link between mitochondrial function, aging, and carcinogenesis. SIRT3 inhibits cancers that depend upon glycolysis, but promotes cancers that depend upon oxidative phosphorylation. Sirt3 functions as a mitochondrial tumor suppressor protein. Although some evidence attributes SIRT3 activity in bypassing growth arrest in bladder carcinoma cells via regulation of p53 in the mitochondria. Damaged and aberrant mitochondrial function, similar to gene mutations, may be an early event that ultimately leads to the development of cancers. Mice genetically altered to delete Sirt3 develop estrogen and progesterone receptor (ER/PR) positive breast mammary tumors. In tumor samples from women with breast cancer, SIRT3 expression was decreased, as compared to normal breast tissues. Thus, the Sirt3 knockout model may be used to investigate ER/PR positive breast tumor development.
Gas chromatography-olfactometry (GC-O) is a technique that integrates the separation of volatile compounds using a gas chromatograph with the detection of odour using an olfactometer (human assessor). It was first invented and applied in 1964 by Fuller and co-workers. While GC separates volatile compounds from an extract, human olfaction detects the odour activity of each eluting compound. In this olfactometric detection, a human assessor may qualitatively determine whether a compound has odour activity or describe the odour perceived, or quantitatively evaluate the intensity of the odour or the duration of the odour activity. The olfactometric detection of compounds allows the assessment of the relationship between a quantified substance and the human perception of its odour, without instrumental detection limits present in other kinds of detectors. Compound identification still requires use of other detectors, such as mass spectrometry, with analytical standards.
==== LRRK2 gene ==== The LRRK2 gene (PARK8) encodes for the protein leucine-rich repeat kinase 2 (LRRK2/dardarin). Mutations in the LRRK2 gene account for the majority of autosomal-dominant Parkinson's disease cases. These mutations are the most common known cause of familial and sporadic PD, accounting for approximately 5% of individuals with a family history of the disease and 1% of apparently sporadic cases. Many individuals carrying LRRK2 mutations do not develop PD, and estimates of the likelihood of developing PD vary widely with different mutations. LRRK2 is reported to have over 100 genetic coding variants. Of these, only six (G2019S, I2020T, R1441C/G/H, and Y1699C) have been reliably shown to be pathogenic, based on PD family groupings, and three more (I1372V, R1628P, and G2385R) are suspected to be PD genetic risk factors. The occurrence of LRRK2 variants differs based on population and ethnicity. G2019S is found in most countries, with higher frequency in Ashkenazi Jewish and Berber populations. R1628P and G2385R appear in Asian populations. LRRK2 is involved in the protein uptake, movement and clearance activities of the endolysosomal system, which degrades and removes unwanted proteins, preventing toxic build-up. LRRK2 and alpha-synuclein interact. Some LRRK2 mutations have been linked to dysfunctional protein degradation and clearance. For example, G2019S mutations appear to reduce the ability to clear alpha-synuclein, the protein which forms Lewy bodies. G2019S may also be linked to tau pathology.
Sources: en.wikipedia.org
=== Reinforced essential nutrients === Deuterium can be used to reinforce specific oxidation-vulnerable C–H bonds within essential or conditionally essential nutrients, such as certain amino acids, or polyunsaturated fatty acids (PUFA), making them more resistant to oxidative damage. Deuterated polyunsaturated fatty acids, such as linoleic acid, slow down the chain reaction of lipid peroxidation that damage living cells. Deuterated ethyl ester of linoleic acid (RT001), developed by Retrotope, is in a compassionate use trial in infantile neuroaxonal dystrophy and has successfully completed a Phase I/II trial in Friedreich's ataxia.
== Contraindications == Caution is required in patients having closed angle glaucoma and in patients with a predisposition to urinary retention as the medication exhibits a relatively small anticholinergic effect. Dose adjustment is required in people who have chronic kidney disease. Liver injury has also been reported. Pizotifen treatment should be discontinued if there is any clinical evidence of liver dysfunction during treatment. Caution is advised in patients having a history of epilepsy. Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decrease have been reported following abrupt cessation of pizotifen. Pizotifen is contraindicated in patients who suffer from hypersensitivity to any of its components or have gastric outlet obstruction, angle-closure glaucoma, and difficulty urinating. In addition, women who are pregnant should not take pizotifen.
=== Underreporting in men === Men often do not report a personal issue of BED. Underreporting could be a result of measurement bias due to how eating disorders are defined. The current definition for eating disorders focuses on thinness. However, eating disorders in men tend to center on muscularity and would therefore warrant a need for a different measurement definition. Overvaluation rates of body weight or shape in adolescent males are significantly lower than their female counterparts (4.9% and 24.2%, respectively). Little is known if this discrepancy is an indicator of later onset of body image distortion in males or a consequence of female-centric diagnostic frameworks for eating disorders. The lack of representation of men in eating disorder research has been hindered by historical perceptions of eating disorders as a "female phenomenon". Researchers have been called on to address this gap by advancing methods of "identification, assessment, classification, and treatment" for eating disorders in a male-specific context, specifically in young men.
Common solvents used in normal or reversed phase LC such as water, acetonitrile, and methanol are all compatible with ESI, yet a LC grade solvent may not be suitable for MS. Furthermore, buffers containing inorganic ions should be avoided as they may contaminate the ion source. Nonetheless, the problem can be resolved by 2D LC-MS, as well as other various issues including analyte coelution and UV detection responses.
I am so relieved. I can't even believe it. Exactly two years ago I was forced to have as much security as possible due to threats. Ever since then, i have never walked alone in the streets. It was heavy. Fortunately, I could still do my job. It was a difficult time in my career. When you hear such news, it is an incredible relief. In 2017, writer Raf Sauviller published his book Borgerokko Maffia, which was distributed to many libraries across Flanders (Belgium) and the Netherlands. In his book, he discusses the corruption that takes place in the Port of Antwerp amongst police officers and Customs controls. According to research which was carried out in 2018, the municipality of Borgerhout, Antwerp, had an illegal economy which was larger than the regular economy due to the influx of funds by the Moroccan mafia. During an interview by the newspaper De Morgen on the context of this book, the mayor of Antwerp, Bart De Wever, admitted that there were many difficulties on intercepting the main commanders of the Moroccan mafia in Antwerp. He also stated:
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.